Cargando…

Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model

BACKGROUND: In 2019 daily liquid methadone and sublingual buprenorphine-naloxone were primary opioid agonist treatments for correctional centres in New South Wales, Australia. However, both had significant potential for diversion to other patients, and their daily administration was resource intensi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, R., White, B., Roberts, J., Cretikos, M., Howard, M. V., Haber, P. S., Lintzeris, N., Reeves, P., Dunlop, A. J., Searles, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644557/ https://www.ncbi.nlm.nih.gov/pubmed/36348369 http://dx.doi.org/10.1186/s12913-022-08687-8

Ejemplares similares

Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings
por: Dunlop, Adrian J., et al.
Publicado: (2021)

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial
por: Lintzeris, Nicholas, et al.
Publicado: (2021)

Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
por: Arunogiri, Shalini, et al.
Publicado: (2021)

Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder
por: Frost, Michael, et al.
Publicado: (2019)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study
por: Larance, Briony, et al.
Publicado: (2020)

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation
por: Ling, Walter, et al.
Publicado: (2019)

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences
por: Neale, Joanne, et al.
Publicado: (2019)

Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum]
Publicado: (2020)

Patient perspectives on depot buprenorphine treatment for opioid addiction – a qualitative interview study
por: Johnson, Björn, et al.
Publicado: (2022)

Strategies for Transfer From Methadone to Buprenorphine for Treatment of Opioid Use Disorders and Associated Outcomes: A Systematic Review
por: Lintzeris, Nicholas, et al.
Publicado: (2022)

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
por: Schmith, Virginia D., et al.
Publicado: (2019)

Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
por: Björnsson, Marcus, et al.
Publicado: (2023)

The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
por: Jackson, Melissa A., et al.
Publicado: (2021)

Opioid prescribing in Australia: too much and not enough
por: Dunlop, Adrian J, et al.
Publicado: (2021)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
por: Andorn, Anne C., et al.
Publicado: (2020)

Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone
por: Elman, Igor, et al.
Publicado: (2020)

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review
por: Soyka, Michael
Publicado: (2021)

Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review
por: Leece, Pamela, et al.
Publicado: (2019)

The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
por: Skoglund, Charlotte, et al.
Publicado: (2022)

Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines
por: Lintzeris, Nicholas, et al.
Publicado: (2018)

Design and in vivo evaluation of a microparticulate depot formulation of buprenorphine for veterinary use
por: Schreiner, Viktoria, et al.
Publicado: (2020)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Author Correction: Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone
por: Elman, Igor, et al.
Publicado: (2020)

Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine
por: Webster, Lynn, et al.
Publicado: (2016)

Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method
por: Hämmig, Robert, et al.
Publicado: (2016)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine
por: Hill, Duncan, et al.
Publicado: (2022)

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials
por: Jones, Aksana K., et al.
Publicado: (2020)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine
por: Gilman, Mark, et al.
Publicado: (2018)

Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE)
por: Schulte, Bernd, et al.
Publicado: (2020)

Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
por: Melichar, J., et al.
Publicado: (2022)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

Personalized Care in Opioid Use Disorder maintained on Buprenorphine
por: Elarabi, H., et al.
Publicado: (2022)

Opioid Drug Utilization and Cost Outcomes Associated With the Use of Buprenorphine-Naloxone in Patients With a History of Prescription Opioid Use
por: Kaur, Aman Deep, et al.
Publicado: (2008)

Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England
por: Aldabergenov, D, et al.
Publicado: (2022)

Estimating the economic costs of skin cancer in New South Wales, Australia
por: Doran, Christopher M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_icf2lclvd69c67l4bour77jem6